Publication:
Oral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix

dc.contributor.authorDavid B. Thomasen_US
dc.contributor.authorRoberta M. Rayen_US
dc.contributor.authorGeoffrey Berryen_US
dc.contributor.authorRobert MacLennanen_US
dc.contributor.authorRodney Shearmanen_US
dc.contributor.authorTatiana Jelihovskyen_US
dc.contributor.authorJoan Cooper Boothen_US
dc.contributor.authorRamiro Molinaen_US
dc.contributor.authorLuis Martinezen_US
dc.contributor.authorOriana Salasen_US
dc.contributor.authorAlfredo Dabancensen_US
dc.contributor.authorAlvaro Cuadrosen_US
dc.contributor.authorNubia Aristizabalen_US
dc.contributor.authorBaruch Modanen_US
dc.contributor.authorElaine Ronen_US
dc.contributor.authorEsther Alfandaryen_US
dc.contributor.authorJ. G. Matien_US
dc.contributor.authorPatrick Kenyaen_US
dc.contributor.authorAlfred Kunguen_US
dc.contributor.authorD. Gateien_US
dc.contributor.authorHector Rodriguez Cuevasen_US
dc.contributor.authorSocorro Benavides Salazaren_US
dc.contributor.authorAntonio Paleten_US
dc.contributor.authorPatricia Ontiverosen_US
dc.contributor.authorRuben A. Apeloen_US
dc.contributor.authorJulietta R. De La Cruzen_US
dc.contributor.authorJose Baensen_US
dc.contributor.authorBenjamin D. Canlasen_US
dc.contributor.authorSuporn Silpisornkosolen_US
dc.contributor.authorTieng Pardthaisongen_US
dc.contributor.authorViruch Charoeniamen_US
dc.contributor.authorChoti Theetranonten_US
dc.contributor.authorBanpot Boosirien_US
dc.contributor.authorSupawat Chutivongseen_US
dc.contributor.authorPramuan Virutamasenen_US
dc.contributor.authorChansuda Wongsrichanalaien_US
dc.contributor.authorSermsri Sindhavanandaen_US
dc.contributor.authorSuporn Koetsawangen_US
dc.contributor.authorDuangdao Rachawaten_US
dc.contributor.authorAmorn Koetsawangen_US
dc.contributor.authorGustave Riottonen_US
dc.contributor.authorWilliam M. Christophersonen_US
dc.contributor.authorJoseph L. Melnicken_US
dc.contributor.authorErvin Adamen_US
dc.contributor.authorOlav Meiriken_US
dc.contributor.authorTimothy M.M. Farleyen_US
dc.contributor.authorSusan Holcken_US
dc.contributor.otherFred Hutchinson Cancer Research Centeren_US
dc.contributor.otherThe University of Sydneyen_US
dc.contributor.otherHospital Universitarioen_US
dc.contributor.otherChaim Sheba Medical Center Israelen_US
dc.contributor.otherUniversity of Nairobien_US
dc.contributor.otherHospital General de Mexicoen_US
dc.contributor.otherUniversity of the Philippines Manilaen_US
dc.contributor.otherChiang Mai Universityen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherUniversite de Geneve Faculte de Medecineen_US
dc.contributor.otherUniversity of Louisville Health Sciences Centeren_US
dc.contributor.otherBaylor College of Medicineen_US
dc.contributor.otherOrganisation Mondiale de la Santeen_US
dc.date.accessioned2018-07-04T07:29:02Z
dc.date.available2018-07-04T07:29:02Z
dc.date.issued1996-08-01en_US
dc.description.abstractData from a hospital-based case-control study collected between 1979 and 1988 in 10 participating hospitals in eight countries were analyzed to determine whether use of combined oral contraceptives alters the risks of invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. Information on prior use of oral contraceptives, suspected risk factors for cervical cancer, and history of cytologic screening was ascertained from interviews with 271 women with adenocarcinomas, 106 with adenosquamous carcinomas, and a large pool of hospitalized controls, from which 2,887 were matched to the cases included in this report. History of smoking and anogenital warts and blood specimens for measurement of herpes simplex and cytomegalovirus antibodies were obtained from subsets of these women, as was a sexual history from a subset of their husbands. The epidemiologic features and associations with oral contraceptives were similar for adenocarcinoma and adenosquamous carcinoma. For both types combined, risk increased with duration of oral contraceptive use, was highest in recent and current users, and declined with time since cessation of use. These trends in risk were strongest for cancers that occurred in women under age 35 years, and the association with risk was somewhat stronger for high compared with low progestin potency products. The strength of the observed relation with oral contraceptives was about the same as has been observed for invasive squamous cell cervical carcinomas. Women who have used oral contraceptives should be considered at increased risk of adenomatous cervical carcinomas.en_US
dc.identifier.citationAmerican Journal of Epidemiology. Vol.144, No.3 (1996), 281-289en_US
dc.identifier.doi10.1093/oxfordjournals.aje.a008923en_US
dc.identifier.issn00029262en_US
dc.identifier.other2-s2.0-9544242825en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/17723
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=9544242825&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleOral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervixen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=9544242825&origin=inwarden_US

Files

Collections